Watchlist
Loading...
HSI16438.71+110.85 +0.68%HSCEI5653.48+43.85 +0.78%HSTECH3734.06+51.39 +1.40%
HK Stock MarketDetailed Quotes

01801 INNOVENT BIO

Watchlist
40.150 -1.450-3.49%
Trading 12/06 15:28 CST
41.600High39.650Low9.15MVolume

About INNOVENT BIO Company

Cinda Biopharmaceuticals is a biopharmaceutical company dedicated to developing, manufacturing and selling high-quality innovative drugs that ordinary people can afford to use. The company was founded by Dr. Yu Dechao in 2011 and has built a multi-functional fully integrated biopharmaceutical platform that meets global quality standards, integrating R&D, clinical development, CMC and commercialization capabilities. The company has established a rich product pipeline, covering a series of innovative therapeutic targets and drug forms (including monoclonal antibodies, multi-specific antibodies, immune cytokines, fusion proteins, T-cell conjugators, antibody-conjugated drugs, cell therapy, small molecule drugs, etc.), covering various major disease fields such as oncology, cardiovascular and metabolic, immunology, and ophthalmology. The product pipeline has huge clinical and commercial potential as a single drug or combination therapy to meet a broad range of medical needs. The company has reached 30 strategic collaborations with international partners such as Eli Lilly, Roche Group, Sanofi, Adimab, Incyte, and the University of Texas Anderson Cancer Center. The company hopes to work with everyone to promote the development of the biopharmaceutical industry, improve the accessibility of medicines and the quality of life for patients.

Company Profile

Symbol01801
Company NameINNOVENT BIO
ISINKYG4818G1010
Listing Date10/31/2018
Issue Price13.98
Shares Offered236.35M share
Founded04/28/2011
RegistrationCayman Islands
ChairmanDechao Yu
SecretaryYanju\chenluoer Wang
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeMaples Corporate Services Limited PO Box 309, Ugland House, Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase I, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees5144
MarketHong Kong motherboard
Phone(86)051269566088
Fax(86)0512695660888348
Emailir@innoventbio.com
Websitehttp://www.innoventbio.com
Business Cinda Biopharmaceuticals is an investment holding company mainly engaged in biopharmaceuticals. The company and its subsidiaries are engaged in the research and development of antibody and protein pharmaceutical products, the sale and distribution of pharmaceuticals, and the provision of consulting and R&D services. The company's main product is dabercib (cindilizumab injection), which is used to treat recurrent or refractory classic Hodgkin lymphoma. The company's products also include the adalimumab antibiotic analogue IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. IBI-305, an antibiotic similar to bevacizumab, is used to treat metastatic colorectal cancer and advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC). IBI-301, an antibiotic similar to rituximab, is used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company's products are used in the fields of oncology, metabolism, immunology and fundus diseases.

Company Executives

  • Name
  • Position
  • Salary
  • Dechao Yu
  • Executive Director，Strategy Committee Chairman，Nomination Committee Chairman，CEO，Chairman，President，Remuneration Committee Member
  • 32.96M
  • Hao Xi
  • CFO，Strategy Committee Member，Authorized Representative，Executive Director
  • 6.96M
  • Charles Leland Cooney
  • Independent Non-Executive Director，Audit Committee Member，Nomination Committee Member，Strategy Committee Member
  • --
  • Yiyin Xu
  • Remuneration Committee Chairman，Independent Non-Executive Director，Audit Committee Chairman
  • 400.00K
  • Kaixian Chen
  • Nomination Committee Member，Remuneration Committee Member，Audit Committee Member，Independent Non-Executive Director
  • 400.00K
  • Gary Zieziula
  • Strategy Committee Member，Independent Non-Executive Director，Audit Committee Member
  • --
  • Yanju Wang
  • Joint Company Secretary
  • --
  • Luoer Chen
  • Joint Company Secretary，Authorized Representative
  • --
Paper Trade Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Buy
Claim up to $1 million virtual fund, join moomoo paper trading today! Claim Now >